Clinical Trial Update: Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial at Tanta University evaluating telmisartan to prevent doxorubicin-induced cardiotoxicity in breast cancer patients; status is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Doxorubicin-induced Cardiomyopathy

Drugs mentioned

• Telmisartan (Telmisartan)

Snippet

Sponsor: Tanta University | Conditions: Breast Cancer, Doxorubicin Induced Cardiomyopathy | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING